Effect of hormone replacement therapy on nitric oxide bioactivity and monocyte chemoattractant protein-1 levels

Kwang Kon Koh, Ji Won Son, Jeong Yeal Ahn, Seon Kyu Lee, Hee Young Hwang, Dae Sung Kim, Dong Kyu Jin, Tae Hoon Ahn, Eak Kyun Shin

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Background: Vascular inflammation plays an important role in the pathogenesis of atherosclerosis. We investigated the effect of hormone replacement therapy (HRT) on vasomotor function and monocyte chemoattractant protein (MCP)-1 levels, an important serological marker of inflammation. Methods: We administered micronized progesterone (MP) 200 mg for 10 days with conjugated equine estrogen (CEE) 0.625 mg for 25 days and remaining 5 days off cyclically during 2 months to 20 healthy postmenopausal women (PMW). We measured NO bioactivity and plasma levels of MCP-1 before and after HRT in 20 PMW. And we measured plasma levels of MCP-1 in each 20 subjects of premenopausal women, men<50, and men>50 years, respectively. Results: MP combined with CEE significantly improved the percent flow-mediated dilator response to hyperemia relative to baseline measurements (P<0.001). PMW receiving HRT had lower levels of MCP-1 than those not receiving HRT (121±38 versus 146±44 pg/ml, P<0.001). In all comparisons, subjects with high estrogen status had significantly lower MCP-1 levels than subjects with low estrogen status (P<0.001 by ANOVA). Premenopausal women had lower levels of MCP-1 than men of a similar age (106±14 versus 164±40 pg/ml, P<0.001). PMW not receiving HRT had similar levels of MCP-1 compared with men of a similar age (146±44 versus 143±29 pg/ml, P=0.816). Premenopausal women had markedly lower levels of MCP-1 than PMW not receiving HRT (106±14 versus 146±44 pg/ml, P=0.001). PMW receiving HRT had similar levels of MCP-1 compared with premenopausal women (121±38 versus 106±14 pg/ml, P=0.323). Conclusion: These findings might provide at least a partial explanation for the protection against cardiovascular disease experienced by premenopausal women, and the loss of that protection following menopause.

Original languageEnglish (US)
Pages (from-to)43-50
Number of pages8
JournalInternational Journal of Cardiology
Volume81
Issue number1
DOIs
StatePublished - Jan 1 2001
Externally publishedYes

Fingerprint

Chemokine CCL2
Hormone Replacement Therapy
Nitric Oxide
Conjugated (USP) Estrogens
Progesterone
Estrogens
Inflammation
Hyperemia
Menopause
Blood Vessels
Atherosclerosis
Analysis of Variance
Cardiovascular Diseases

Keywords

  • Atherosclerosis
  • Endothelium
  • Hormone replacement therapy
  • Menopause
  • Monocyte chemoattractant protein
  • Nitric oxide bioactivity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effect of hormone replacement therapy on nitric oxide bioactivity and monocyte chemoattractant protein-1 levels. / Koh, Kwang Kon; Won Son, Ji; Yeal Ahn, Jeong; Lee, Seon Kyu; Young Hwang, Hee; Sung Kim, Dae; Kyu Jin, Dong; Hoon Ahn, Tae; Kyun Shin, Eak.

In: International Journal of Cardiology, Vol. 81, No. 1, 01.01.2001, p. 43-50.

Research output: Contribution to journalArticle

Koh, KK, Won Son, J, Yeal Ahn, J, Lee, SK, Young Hwang, H, Sung Kim, D, Kyu Jin, D, Hoon Ahn, T & Kyun Shin, E 2001, 'Effect of hormone replacement therapy on nitric oxide bioactivity and monocyte chemoattractant protein-1 levels', International Journal of Cardiology, vol. 81, no. 1, pp. 43-50. https://doi.org/10.1016/S0167-5273(01)00527-7
Koh, Kwang Kon ; Won Son, Ji ; Yeal Ahn, Jeong ; Lee, Seon Kyu ; Young Hwang, Hee ; Sung Kim, Dae ; Kyu Jin, Dong ; Hoon Ahn, Tae ; Kyun Shin, Eak. / Effect of hormone replacement therapy on nitric oxide bioactivity and monocyte chemoattractant protein-1 levels. In: International Journal of Cardiology. 2001 ; Vol. 81, No. 1. pp. 43-50.
@article{fc883a19760145bebd064056065a1914,
title = "Effect of hormone replacement therapy on nitric oxide bioactivity and monocyte chemoattractant protein-1 levels",
abstract = "Background: Vascular inflammation plays an important role in the pathogenesis of atherosclerosis. We investigated the effect of hormone replacement therapy (HRT) on vasomotor function and monocyte chemoattractant protein (MCP)-1 levels, an important serological marker of inflammation. Methods: We administered micronized progesterone (MP) 200 mg for 10 days with conjugated equine estrogen (CEE) 0.625 mg for 25 days and remaining 5 days off cyclically during 2 months to 20 healthy postmenopausal women (PMW). We measured NO bioactivity and plasma levels of MCP-1 before and after HRT in 20 PMW. And we measured plasma levels of MCP-1 in each 20 subjects of premenopausal women, men<50, and men>50 years, respectively. Results: MP combined with CEE significantly improved the percent flow-mediated dilator response to hyperemia relative to baseline measurements (P<0.001). PMW receiving HRT had lower levels of MCP-1 than those not receiving HRT (121±38 versus 146±44 pg/ml, P<0.001). In all comparisons, subjects with high estrogen status had significantly lower MCP-1 levels than subjects with low estrogen status (P<0.001 by ANOVA). Premenopausal women had lower levels of MCP-1 than men of a similar age (106±14 versus 164±40 pg/ml, P<0.001). PMW not receiving HRT had similar levels of MCP-1 compared with men of a similar age (146±44 versus 143±29 pg/ml, P=0.816). Premenopausal women had markedly lower levels of MCP-1 than PMW not receiving HRT (106±14 versus 146±44 pg/ml, P=0.001). PMW receiving HRT had similar levels of MCP-1 compared with premenopausal women (121±38 versus 106±14 pg/ml, P=0.323). Conclusion: These findings might provide at least a partial explanation for the protection against cardiovascular disease experienced by premenopausal women, and the loss of that protection following menopause.",
keywords = "Atherosclerosis, Endothelium, Hormone replacement therapy, Menopause, Monocyte chemoattractant protein, Nitric oxide bioactivity",
author = "Koh, {Kwang Kon} and {Won Son}, Ji and {Yeal Ahn}, Jeong and Lee, {Seon Kyu} and {Young Hwang}, Hee and {Sung Kim}, Dae and {Kyu Jin}, Dong and {Hoon Ahn}, Tae and {Kyun Shin}, Eak",
year = "2001",
month = "1",
day = "1",
doi = "10.1016/S0167-5273(01)00527-7",
language = "English (US)",
volume = "81",
pages = "43--50",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Effect of hormone replacement therapy on nitric oxide bioactivity and monocyte chemoattractant protein-1 levels

AU - Koh, Kwang Kon

AU - Won Son, Ji

AU - Yeal Ahn, Jeong

AU - Lee, Seon Kyu

AU - Young Hwang, Hee

AU - Sung Kim, Dae

AU - Kyu Jin, Dong

AU - Hoon Ahn, Tae

AU - Kyun Shin, Eak

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Background: Vascular inflammation plays an important role in the pathogenesis of atherosclerosis. We investigated the effect of hormone replacement therapy (HRT) on vasomotor function and monocyte chemoattractant protein (MCP)-1 levels, an important serological marker of inflammation. Methods: We administered micronized progesterone (MP) 200 mg for 10 days with conjugated equine estrogen (CEE) 0.625 mg for 25 days and remaining 5 days off cyclically during 2 months to 20 healthy postmenopausal women (PMW). We measured NO bioactivity and plasma levels of MCP-1 before and after HRT in 20 PMW. And we measured plasma levels of MCP-1 in each 20 subjects of premenopausal women, men<50, and men>50 years, respectively. Results: MP combined with CEE significantly improved the percent flow-mediated dilator response to hyperemia relative to baseline measurements (P<0.001). PMW receiving HRT had lower levels of MCP-1 than those not receiving HRT (121±38 versus 146±44 pg/ml, P<0.001). In all comparisons, subjects with high estrogen status had significantly lower MCP-1 levels than subjects with low estrogen status (P<0.001 by ANOVA). Premenopausal women had lower levels of MCP-1 than men of a similar age (106±14 versus 164±40 pg/ml, P<0.001). PMW not receiving HRT had similar levels of MCP-1 compared with men of a similar age (146±44 versus 143±29 pg/ml, P=0.816). Premenopausal women had markedly lower levels of MCP-1 than PMW not receiving HRT (106±14 versus 146±44 pg/ml, P=0.001). PMW receiving HRT had similar levels of MCP-1 compared with premenopausal women (121±38 versus 106±14 pg/ml, P=0.323). Conclusion: These findings might provide at least a partial explanation for the protection against cardiovascular disease experienced by premenopausal women, and the loss of that protection following menopause.

AB - Background: Vascular inflammation plays an important role in the pathogenesis of atherosclerosis. We investigated the effect of hormone replacement therapy (HRT) on vasomotor function and monocyte chemoattractant protein (MCP)-1 levels, an important serological marker of inflammation. Methods: We administered micronized progesterone (MP) 200 mg for 10 days with conjugated equine estrogen (CEE) 0.625 mg for 25 days and remaining 5 days off cyclically during 2 months to 20 healthy postmenopausal women (PMW). We measured NO bioactivity and plasma levels of MCP-1 before and after HRT in 20 PMW. And we measured plasma levels of MCP-1 in each 20 subjects of premenopausal women, men<50, and men>50 years, respectively. Results: MP combined with CEE significantly improved the percent flow-mediated dilator response to hyperemia relative to baseline measurements (P<0.001). PMW receiving HRT had lower levels of MCP-1 than those not receiving HRT (121±38 versus 146±44 pg/ml, P<0.001). In all comparisons, subjects with high estrogen status had significantly lower MCP-1 levels than subjects with low estrogen status (P<0.001 by ANOVA). Premenopausal women had lower levels of MCP-1 than men of a similar age (106±14 versus 164±40 pg/ml, P<0.001). PMW not receiving HRT had similar levels of MCP-1 compared with men of a similar age (146±44 versus 143±29 pg/ml, P=0.816). Premenopausal women had markedly lower levels of MCP-1 than PMW not receiving HRT (106±14 versus 146±44 pg/ml, P=0.001). PMW receiving HRT had similar levels of MCP-1 compared with premenopausal women (121±38 versus 106±14 pg/ml, P=0.323). Conclusion: These findings might provide at least a partial explanation for the protection against cardiovascular disease experienced by premenopausal women, and the loss of that protection following menopause.

KW - Atherosclerosis

KW - Endothelium

KW - Hormone replacement therapy

KW - Menopause

KW - Monocyte chemoattractant protein

KW - Nitric oxide bioactivity

UR - http://www.scopus.com/inward/record.url?scp=0034749552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034749552&partnerID=8YFLogxK

U2 - 10.1016/S0167-5273(01)00527-7

DO - 10.1016/S0167-5273(01)00527-7

M3 - Article

C2 - 11690664

AN - SCOPUS:0034749552

VL - 81

SP - 43

EP - 50

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 1

ER -